Cargando…
Generation and characterization of a mitotane-resistant adrenocortical cell line
Mitotane is the only drug approved for the therapy of adrenocortical carcinoma (ACC). Its clinical use is limited by the occurrence of relapse during therapy. To investigate the underlying mechanisms in vitro, we here generated mitotane-resistant cell lines. After long-term pulsed treatment of HAC-1...
Autores principales: | Seidel, Eric, Walenda, Gudrun, Messerschmidt, Clemens, Obermayer, Benedikt, Peitzsch, Mirko, Wallace, Paal, Bahethi, Rohini, Yoo, Taekyeong, Choi, Murim, Schrade, Petra, Bachmann, Sebastian, Liebisch, Gerhard, Eisenhofer, Graeme, Beule, Dieter, Scholl, Ute I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993260/ https://www.ncbi.nlm.nih.gov/pubmed/31910152 http://dx.doi.org/10.1530/EC-19-0510 |
Ejemplares similares
-
Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994) -
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022) -
Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018) -
The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019) -
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)